Background Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high
(MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The …

Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch repair-…

Gastric cancer is considered an age-related disease, with the majority of new cases in the
UK diagnosed in individuals over the age of 75. At present most guidance related to the …

ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC…

LBA4 Background: KEYNOTE-177 (NCT02563002) is a phase 3, randomized open-label
study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard of care …

Background In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically
significant and clinically meaningful improvements in progression-free survival versus …

Gastrointestinal cancers include colorectal, gastric, oesophageal, pancreatic and liver
cancers. They continue to be a significant cause of mortality and morbidity worldwide. Current …

Adenoid cystic carcinoma (AdCC) is a rare form of triple‐negative and basal‐like breast
cancer that has an indolent clinical behaviour. Four breast AdCCs were recently shown to …

The design of targeted therapeutic strategies for cancer has largely been driven by the
identification of tumor-specific genetic changes. However, the large number of genetic alterations …

Background & Aims Colorectal cancer (CRC) shows variable response to immune checkpoint
blockade, which can only partially be explained by high tumor mutational burden (TMB). …